Aussie Peptides · AU
MK-677 (Ibutamoren) 25mg
$119.00
Why Aussie Peptides
Lot-matched certificate
Independently analysed before release; look the lot up on the verification page.
Strictly research use
Not for human or veterinary consumption.
Express AU shipping
Discreet, fully tracked, 1–3 business days.
Aussie Peptides · specification
MK-677 (Ibutamoren) 25mg
- Presentation
- 25mg sealed vial
- SKU
- MK-677-IBUTAMOREN-25MG
- Format
- Research-grade powder
- Purity
- ≥99% release specification by RP-HPLC — result recorded per lot
- Documentation
- Batch-specific Certificate of Analysis
- Storage
- 2–8 °C, protect from light
- Dispatch
- Cold-chain, same-day, Australia-wide
- Origin
- Packed in Australia · Aussie Peptides
- Category
- Longevity
Specifications are standardised across the Aussie Peptides range. Batch values — lot number, assay result and expiry — are printed on the vial and matched to the Certificate of Analysis supplied with your order.
The Aussie Peptides label
- 1
Coral spine + hexagon mark
Every Aussie Peptides vial carries the same coral spine and molecular hexagon so a genuine vial is recognisable at a glance.
- 2
Compound, strength, fill volume
Printed in a fixed position on the cream label — compound name, strength in milligrams, and vial volume.
- 3
LOT + EXP fields
Hand-stamped per batch and matched to the Certificate of Analysis you can look up on our CoA page.
- 4
Lot-tested by RP-HPLC — research use only
The compliance line appears on every label, on every SKU, without exception.
Laboratory handling · Non-peptide research powder
Usage & handling guide
Supplied as a bulk research-grade powder. Prepared gravimetrically in an organic vehicle rather than reconstituted in water.
- Reconstitution
- Weigh gravimetrically; prepare stock in a validated organic vehicle (e.g. DMSO)
- Stock concentration
- Set by your protocol — commonly 10–50 mM master stock
- Storage once reconstituted
- −20 °C, amber or foil-wrapped, desiccated
- Stability window
- Master stock typically stable for several months at −20 °C; avoid repeated warm–cool cycles
1 · Weigh under controlled conditions
Weigh the research-grade powder on a calibrated analytical balance in a draught-free enclosure. Record the tare and net mass for every preparation.
2 · Dissolve in the appropriate vehicle
This compound is not water-soluble at bench concentrations. Prepare stocks in a suitable organic vehicle (commonly DMSO) validated for your assay system.
3 · Confirm full dissolution
Warm gently to 25–37 °C and mix until the solution is optically clear before any dilution step.
4 · Dilute into assay media last
Serially dilute into media immediately before use and keep the final vehicle concentration within the tolerance of your model system.
5 · Aliquot and protect from light
Store aliquots in amber or foil-wrapped tubes; avoid repeated warming of the master stock.
6 · Record against the CoA
Log the LOT number and batch Certificate of Analysis reference with every preparation for full traceability.
Figures above are worked examples for bench preparation only. Always calculate your own working concentrations from the strength printed on the vial, the exact diluent volume you added, and the batch assay result on the Certificate of Analysis.
Safety & handling cautions
- Handle powder in a fume hood or ventilated enclosure with appropriate PPE — avoid inhalation of fine powder.
- Verify vehicle tolerance in your model system before use; vehicle-only controls are essential.
- Wear appropriate PPE, work in a clean and controlled area, and dispose of vials, sharps and unused stock in line with your institution’s waste procedures.
Important — no dosage advice
This guide covers reconstitution, storage and laboratory handling only. Aussie Peptides does not publish, supply or advise on human or veterinary dosing, administration schedules, or therapeutic protocols for any product, and nothing here should be interpreted as such.
All products are supplied strictly for in-vitro laboratory research by qualified professionals. They are not medicines, are not evaluated by the TGA, and are not for human or animal consumption. Nothing on this page is medical advice — speak to a qualified healthcare professional about any health matter.
In depth
MK-677 (Ibutamoren) in Australia — research notes
MK-677 (Ibutamoren) is a non-peptide, orally active ghrelin-receptor agonist supplied as 25mg research-grade powder.
- Non-peptide oral GHS-R1a agonist, 25mg powder
- Long half-life — sustained rather than pulsatile signalling
- Compare directly with Ipamorelin
Not a peptide at all
MK-677 is a spiroindane small molecule, which is why it survives oral administration in animal models where peptide secretagogues do not. It is the only compound in this range that is not a peptide, and it handles differently as a result.
Long exposure window
Its extended half-life produces sustained GHS-R1a occupancy rather than the pulsatile pattern seen with Ipamorelin or GHRP-2 — the central variable in comparative studies between the two classes.
Handling powder rather than lyophilised peptide
Supplied as a dry research powder; solvent choice differs from bacteriostatic-water reconstitution. Every vial ships from our Australian storage and dispatch facility with a lot-matched certificate of analysis and cold-chain packaging.
About this compound
Research overview
MK-677 (Ibutamoren) is an orally bioavailable ghrelin receptor agonist researched for sustained 24-hour elevation of GH and IGF-1.Research benefits Sustained GH and IGF-1 elevation Supports sleep depth and recovery Oral, no injection required Capsules manufactured in Australia. Independently assayed.
Compliance
For in‑vitro research only.
Products supplied for laboratory research. Not for human or veterinary consumption. Buyer assumes all responsibility.
Read compliance →Questions
MK-677 (Ibutamoren) 25mg — frequently asked
What is MK-677 (Ibutamoren)?+
MK-677 (Ibutamoren) is an orally bioavailable ghrelin receptor agonist researched for sustained 24-hour elevation of GH and IGF-1.Research benefits Sustained GH and IGF-1 elevation Supports sleep depth and recovery Oral, no injection required Capsules manufactured in Australia. Independently assayed. Aussie Peptides supplies MK-677 (Ibutamoren) strictly as an in-vitro laboratory reference material — it is not a therapeutic good and is not for human or veterinary use.
How pure is Aussie Peptides MK-677 (Ibutamoren)?+
Each MK-677 (Ibutamoren) lot is analysed by RP-HPLC for purity and by mass spectrometry for identity, and is released against a ≥99% purity specification. The result belongs to that lot: the number printed on your vial maps to its own Certificate of Analysis, so the figure can be recorded alongside your experimental data rather than assumed.
How is MK-677 (Ibutamoren) 25mg reconstituted and stored in the lab?+
Weigh gravimetrically; prepare stock in a validated organic vehicle (e.g. DMSO) That gives a working stock of roughly Set by your protocol — commonly 10–50 mM master stock. Reconstituted vials are held at −20 °c, amber or foil-wrapped, desiccated, and master stock typically stable for several months at −20 °c; avoid repeated warm–cool cycles Sealed lyophilised 25mg vials are stable long-term at -20°C.
Is it legal to buy MK-677 (Ibutamoren) in Australia?+
MK-677 (Ibutamoren) is supplied in Australia for in-vitro laboratory research only. It is not approved by the TGA as a therapeutic good and is not sold for human or veterinary consumption. Purchasers must be 18 or over and are responsible for handling, storage and disposal under their own institutional and legal requirements.
How much is MK-677 (Ibutamoren) 25mg and how fast does it ship?+
MK-677 (Ibutamoren) 25mg is $119.00. It is in stock and dispatched same business day on orders placed before 12pm AEST. Shipping is A$12.95 express Australia-wide and free over A$199, sent discreetly packaged and fully tracked, typically 1–3 business days.
What does the research on MK-677 (Ibutamoren) investigate?+
Published work on this class focuses on cellular senescence, mitochondrial and NAD+ pathways, and telomere-related endpoints in laboratory models. Nothing on this page is a dosing protocol, medical advice, or a claim of therapeutic benefit — it summarises what the published literature examines.
Keep exploring
